Agios Pharmaceuticals, Inc.
Support and Resistance Levels
Past performance
News About AGIO
All events for AGIO
All deals for AGIO
Financial Ratios
Financial Statements
AGIO vs Sector & Peers
About Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts. Website agios.com
Headquarters Cambridge, MA, US